Abstract | BACKGROUND: Because of their size and the possibility of complications, giant hemangiomas represent a therapeutic challenge. Various forms of treatment have been used, with variable results, including surgery, embolization, lasers, pentoxifylline, and corticosteroids. Interferon alfa has been used successfully to treat life-threatening hemangiomas, possibly by means of its antiangiogenic activity. OBSERVATIONS: CONCLUSIONS:
Interferon alfa-2b is a good option for the treatment of patients with steroid-resistant, organ-interfering and/or life-threatening giant hemangiomas. In our experience, the adverse effects were transient and minor and did not require the interruption of the treatment.
|
Authors | L Tamayo, D M Ortiz, L Orozco-Covarrubias, C Durán-McKinster, M A Mora, E Avila, F Teixeira, R Ruiz-Maldonado |
Journal | Archives of dermatology
(Arch Dermatol)
Vol. 133
Issue 12
Pg. 1567-71
(Dec 1997)
ISSN: 0003-987X [Print] United States |
PMID | 9420543
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Interferon alpha-2
- Interferon-alpha
- Recombinant Proteins
|
Topics |
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Drug Evaluation
- Eyelid Neoplasms
(diagnosis, therapy)
- Facial Neoplasms
(diagnosis, therapy)
- Female
- Head and Neck Neoplasms
(diagnosis, therapy)
- Hemangioma
(diagnosis, therapy)
- Humans
- Infant
- Injections, Subcutaneous
- Interferon alpha-2
- Interferon-alpha
(administration & dosage, adverse effects)
- Male
- Prospective Studies
- Recombinant Proteins
- Skin Neoplasms
(diagnosis, therapy)
- Time Factors
|